237 In the index

Meldonium MELD

A heart medication approved in some Eastern European countries but not in the U.S., which became widely known after tennis star Maria Sharapova tested positive for it. Where it's approved, studies support benefits for heart conditions with reduced blood flow, though evidence for boosting athletic performance comes more from doping cases than dedicated performance studies.

Also known as Mildronate, Kvaterin, 3-(2,2,2-trimethylhydrazine)propionate, Quaterine, 3-(2,2,2-Trimethyldiazaniumyl)propanoate, meldonio, MET-88

Effects Endurance

Routes Oral

Legal status Unapproved / investigational

WADA Banned at all times

3D Molecular Structure of C₆H₁₄N₂O₂

Drag to rotate · scroll to zoom

Chemistry

Formula: C6H14N2O2
Molar mass: 146.19
CAS: 76144-81-5
PubChem CID: 123868
IUPAC name: 3-[(trimethylazaniumyl)amino]propanoate
InChIKey: PVBQYTCFVWZSJK-UHFFFAOYSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 500 mg/day

Reported range 500-1000 mg/day

Route Oral

Frequency Once or twice daily

Duration 4-6 week course, as used clinically in approved markets

Approved in Russia/Baltic states (as Mildronate) for cardiovascular conditions; not FDA-approved. Banned by WADA since 2016 after widespread use was found among elite athletes.

Where this comes from Regional prescribing information (Latvia/Russia); anti-doping literature

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.